Golden Adam H. 4

What Happened Adam H. Golden, General Counsel of Avalyn Pharma, was granted a derivative equity award of 254,891 shares on April 29, 2026. The award is reported as a derivative instrument with an acquisition price of $0.00 (no cash paid at grant). This was a compensation grant (option award), not a market purchase or sale.

Key Details

• Transaction date: 2026-04-29; reported on Form 4 filed 2026-05-04 (appears to be filed after the typical 2-business-day reporting window).
• Instrument: derivative (option) covering 254,891 shares; reported acquisition price $0.00; reported value $0 on Form 4.
• Vesting (per footnote): 25% of the shares underlying the option vest and become exercisable on April 23, 2027; the remaining 75% vest in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: not specified in the filing.
• No indication of a sale, exercise, tax withholding, or 10b5-1 plan in the filing.

Context This was an option grant as part of compensation and does not represent an immediate purchase or sale of shares. Vesting is conditioned on continued employment; options only translate into actual shares if/when exercised according to the vesting schedule. The filing date suggests the Form 4 was submitted several days after the grant date, which may be later than the standard 2-business-day reporting requirement.